[整合基于AI的技术来检测与痴呆相关的行为障碍]
1Haute école de santé Valais/Wallis (HES-SO), chemin de l'Agasse 5, 1950 Sion, Suisse; Fondation les Maisons de la Providence, chemin de Pierra-Barna 18, Montagnier, Suisse.
Soins; la revue de reference infirmiere
|October 9, 2025
概括
早期发现痴呆症的行为和心理症状对于有效管理至关重要. 人工智能和实时医疗保健技术对管理这些症状充满希望,但早期检测应用程序仍在开发中.
科学领域:
- 老年学是一门学科.
- 神经科学是一个神经科学.
- 医疗保健中的人工智能
背景情况:
- 痴呆症的行为和心理症状 (BPSD) 显著影响患者的福祉和护理.
- 当前的医疗保健系统在管理BPSD的复杂性方面面临着挑战.
研究的目的:
- 探索用于管理BPSD的创新和可持续解决方案.
- 研究人工智能 (AI) 和实时医疗保健技术在BPSD管理和早期检测方面的潜力.
主要方法:
- 审查人工智能,面部识别和机器人在痴呆症护理中的当前应用.
- 分析这些技术在实时症状管理中的潜力.
- 评估目前使用这些技术用于早期BPSD检测的局限性.
主要成果:
- 基于人工智能的设备,面部识别和机器人技术越来越多地用于管理BPSD.
- 这些技术为实时症状监测和干预提供了潜力.
- 这些技术用于早期检测BPSD的应用仍然不发达.
结论:
- 像人工智能这样的创新技术有望改善BPSD管理.
- 需要进一步的研究和开发,以利用这些技术进行早期BPSD检测.
- 通过技术进步解决医疗保健系统的局限性对于痴呆症护理至关重要.
相关概念视频
Dementia
517
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
517
Alzheimer's Disease: Treatment
822
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
822
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K


